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13 years (children) [22.7%], 13-17 years (adolescents) [17.3%], 18-40 years [30.0%], and 
> 40 years [30.0%]. The prevalence of HbA1c, FBS, and lipid panel testing significantly 
differed among the groups overall, and increased with increasing age, for both FGAs 
and SGAs. ConClusions: It is recommended that patients taking antipsychotics 
be tested regularly for glucose and lipid changes. Only about one-third of patients 
taking antipsychotic medications had a lipid panel test, and less than one-fifth had 
an HbA1c or FBS test during the 12 months of analysis.
PMH74
TreaTMenT PaTTerns and HealTH Care CosTs in PaTienTs wiTH 
sCHizoPHrenia iniTiaTing wiTH FirsT- or seCond-generaTion 
anTiPsyCHoTiC: resulTs FroM a JaPanese ClaiMs daTabase analysis
Jamotte A.1, Clay E.1, Aballéa S.1, Onishi Y.2, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Sanofi K.K., Tokyo, Japan, 3University of Marseille,  
Marseille, France
objeCtives: To describe and compare treatment patterns and health care costs in 
patients with schizophrenia initiating treatment with first-generation antipsychotic (s) 
(FGA) and patients initiating treatment with second-generation antipsychotic (s) 
(SGA) using claims database in Japan. Methods: Using data from the Japan Medical 
Data Center (JMDC) database, a retrospective longitudinal cohort study was con-
ducted, including adults aged 18-65 years with a first prescription of antipsychotic 
(index date) between January 2009 and September 2013, and diagnosed with schiz-
ophrenia around index date. Time to treatment discontinuation (gap of 90 days 
without antipsychotic treatment), time to switch, time to psychiatric hospitalisation 
and total costs at 6 and 12 months were estimated for each group (FGA vs. SGA), 
and compared, with adjustment on potential confounders (gender, age, insurance 
status, index year and baseline costs) using Cox proportional-hazards regression 
and log-linear regression models. Results: 2,615 patients were included (14% ini-
tiating treatment with FGA and 86% initiating with SGA). 55.0% were female, with 
no significant difference between the groups (p= 0.22). FGA patients were older than 
SGA patients (40.1 years vs. 34.1, p< 0.0001). The total health care costs at 6 months 
were significantly higher in FGA patients (¥1,489,680 vs. ¥324,595; p< 0.0001). After 
adjustment, FGA treatment was associated with higher costs at 6 months (+121%, 
IC95%: [+93%; +152%], p< 0.0001), and at 12 months (+87%, IC95%: [+60%; +119%], 
p< 0.0001). Time to discontinuation as well as time to hospitalisation were shorter 
for the FGA group but did not reach significance (HR= 1.146, p= 0.09; HR= 1.406, p= 0.07 
respectively). The probability of switching was higher in the FGA group (HR: 5.281, 
p< 0.0001). ConClusions: A large proportion of patients with schizophrenia were 
treated with SGA at initiation, consistently with previous studies conducted in 
Japan. Patients treated with SGA tend to have longer treatment duration and lower 
costs than patients treated with FGA.
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objeCtives: To compare the efficacy and tolerability of oral first-line antimus-
carinic agents recommended for the treatment of OAB. Methods: Literature 
searches were undertaken to identify published randomised controlled trials 
(2000–2012), which reported efficacy and/or tolerability in adults receiving phar-
macological treatment for OAB. Bayesian MTC methodology was used to assess 
changes from baseline in micturition frequency per 24h, urgency, incontinence, 
and urge incontinence (UI). Safety outcomes included dry mouth, constipation, and 
blurred vision. Results: Forty-one eligible trials involving 25,118 patients were 
included in the MTC. Solifenacin 5mg was significantly more effective than darifena-
cin 7.5mg based on incontinence (mean difference [MD]= 0.531/day), fesoterodine 
4mg based on micturition (MD= 0.374/day), and tolterodine 4mg based on micturi-
tion (MD= 0.387/day), urgency (MD= 0.434/day), incontinence (MD= 0.309/day), and 
UI (MD= 0.416/day). However, the starting dose of solifenacin 5mg was significantly 
less effective than solifenacin 10mg according to micturition (MD= –0.343/day), and 
urgency (MD= –0.391/day). No other significant efficacy differences were reported. 
Solifenacin 5mg had a significantly lower risk of dry mouth compared to oxybutynin 
(intermediate-release) IR 9mg (odds ratio [OR]= 2.732) or 10mg (OR= 3.534), oxybu-
tynin extended-release (ER) 10mg (OR= 1.714), tolterodine IR 4mg (OR= 1.763), and 
solifenacin 10mg (OR= 2.470). Tolterodine ER 4mg (OR= 0.481) or IR 4mg (OR= 0.440), 
oxybutynin IR 9mg (OR= 0.429) or ER 10mg (OR= 0.440), and fesoterodine 4mg 
(OR= 0.463) were associated with a significantly lower risk of constipation than 
solifenacin 5mg. Solifenacin 10mg was associated with a higher risk of constipation 
(OR= 1.804) and blurred vision (OR= 1.730) than solifenacin 5mg. ConClusions: 
This MTC suggests that the 5mg starting dose of solifenacin is more effective than 
the 4mg starting dose of tolterodine in reducing symptoms of OAB; solifenacin 5mg 
also has similar or better efficacy than the starting doses of other antimuscarinic 
agents across the spectrum of symptoms analysed. The lower risk of dry mouth with 
solifenacin 5mg may deliver improved treatment persistence.
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identifying Veterans at risk for poor mental health may be working to provide health 
care benefit coverage but the persistence of symptoms, amongst those enrolled, may 
suggest a need for improved treatment or surveillance.
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objeCtives: Major depressive disorder is characterised by the presence of one 
or more major depressive episodes. Up to one-third of patients do not adequately 
respond to first-line therapies. In case of treatment failure, the most common strat-
egy is to switch to another antidepressant drug (AD). However, patients may have 
been exposed in prior episodes to one or more other ADs, which could impact 
the efficacy of subsequent treatments. This study describes historical AD use in 
depressed patients undergoing treatment switch. Methods: This retrospective lon-
gitudinal cohort study used a database of medical records from general practition-
ers located throughout the UK (CPRD). Adult patients with a depression diagnosis 
undergoing an AD switch between 01/01/2012 and 30/06/2013 and with no diagnosis 
of schizophrenia or bipolar disorder were included. Historical AD use was assessed 
on all available prescriptions prior to switch and was grouped by treatment class 
(SSRI, SNRI, TCA and others). Results: 11,611 patients were identified. Their mean 
age was 44.5 years (SD= 16.18) and 66.7% were women. Prior to switch, patients used 
2.65 different classes of ADs on average (SD= 1.89); at least two different classes of 
ADs were prescribed for 64.8% of patients. Before the switch, SSRIs were the most 
common (1.65/patient) followed by TCAs (0.51/patient), other ADs (0.31/patient) 
and SNRIs (0.18/patient). Significant proportions of patients had previously been 
prescribed several AD classes: 34.1% of patients received at least one SSRI and one 
TCA, 24.0% at least one SNRI and one TCA, 15.0% at least one SSRI and one SNRI, 
and 13.7% at least one TCA and one other AD prior to AD switch. ConClusions: 
This analysis showed that for patients initiating an AD switch, historical use of ADs 
was very common, and that a substantial proportion of patients had already been 
prescribed several ADs, thereby reducing the treatment options for future switches.
PMH72
TreaTMenT PaTTerns and HealTH Care CosTs in PaTienTs wiTH 
dePression TreaTed wiTH anTidePressanT only or CoMbined wiTH 
benzodiazePine: resulTs FroM a JaPanese ClaiMs daTabase analysis
Jamotte A.1, Clay E.1, Onishi Y.2, Aballéa S.1, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Sanofi K.K., Tokyo, Japan, 3University of Marseille,  
Marseille, France
objeCtives: To describe and compare treatment patterns and health care costs in 
patients with depression initiating treatment with antidepressant (AD) (in mono-
therapy or in combination) and patients initiating AD treatment combined with 
benzodiazepine (BZD) using claims database in Japan. Methods: Using data from 
the Japan Medical Data Center (JMDC) database, a retrospective longitudinal cohort 
study was conducted, including adults aged 18-65 years with a first prescription 
of AD (index date) between January 2009 and September 2013, and diagnosed with 
major depression around index date. Time to treatment discontinuation (gap of 90 
days without AD treatment) and total costs at 6 and 12 months were estimated for 
each group (AD vs. AD+BZD), and compared, with adjustment on potential con-
founders (gender, age, insurance status, index year and baseline costs) using Cox 
proportional-hazards regression and log-linear regression models. Results: 7,723 
patients were included (43.7% initiating treatment with AD+BZD and 56.3% initiat-
ing with AD). Mean age of the population was 36.5 years and 59.1% were males, with 
no significant differences found between the groups (p= 0.14 and p= 0.39 respec-
tively). The total health care costs at 6 months were significantly higher in AD+BZD 
patients (¥176,946 vs. ¥151,992; p< 0.0001). After adjustment, AD+BZD treatment was 
associated with higher costs at 6 months (+5.2%, IC95%: [+4.7 %; +5.8 %], p< 0.0001) 
and at 12 months (+6.4%, IC95%: [+5.7%; +7.1%], p< 0.0001). Time to discontinuation 
was longer for the AD+BZD group (HR= 0.758, p< 0.0001). ConClusions: A large 
proportion of patients with depression were treated with AD+BZD at initiation, a 
practice not recommended in Japanese guidelines. Patients treated with AD+BZD 
tend to have higher costs than patients treated with AD. The combination with BZD 
is associated with longer treatment duration and further analyses are recommended 
to determine if this is related to improved persistence or longer time to remission.
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objeCtives: Patients taking antipsychotics are at higher risk for other co-morbid 
diseases, including metabolic-related conditions. The objective of this study was to 
determine the level of testing for potential medication-related co-morbidities, looking 
at rates of Hemoglobin A1c (HbA1c) and fasting blood sugar (FBS) tests for diabetes as 
well as lipid panel tests for hyperlipidemia. Methods: Using Texas Medicaid claims 
for 2012, a total of 135,757 patients filled at least one prescription for an antipsychotic 
medication. Claims data on lab testing were extracted for these patients. Results: 
Overall, 36.0% of patients taking antipsychotics received a lipid panel test, 18.7% 
received an HbA1c test, and only 6.5% received a FBS test. Nine percent and 95.8% of 
patients had claims for first- and second-generation antipsychotics (FGAs and SGAs), 
respectively [some patients had both prescribed]. A total of 53.5% were male and 46.5% 
were female. A larger proportion of patients taking FGAs had HbA1c, FBS, and lipid 
panel tests compared to patients taking SGAs: 28.9% vs. 18.4% (HbA1c); 8.1% vs. 6.4% 
(FBS); 49.8% vs. 35.6% (lipid panel). A larger proportion of females had HbA1c, FBS, 
and lipid panel tests compared to males: 23.4% vs. 14.8% (HbA1c); 7.6% vs. 5.6% (FBS); 
40.7% vs. 32.3% (lipid panel). In addition, patients were divided into four age groups: < 
